¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reversed passive anaphylaxis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive aggressive personality
    ¼öµ¿°ø°ÝÀΰÝ
  • passive congestion
    ¼öµ¿¿ïÇ÷
  • passive diffusion
    ¼öµ¿È®»ê
  • passive edema
    ¼öµ¿ºÎÁ¾
  • passive euthanasia
    ¼Ò±ØÀû¾È¶ô»ç
  • passive exercise
    Çǵ¿¿îµ¿
  • passive hemagglutination
    ¼öµ¿ÀûÇ÷±¸ÀÀÁý
  • passive hyperemia
    ¼öµ¿ÃæÇ÷
  • passive immunity
    ¼öµ¿¸é¿ª
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • passive movement
    ¼öµ¿¿îµ¿, Çǵ¿¿îµ¿
  • passive observer
    ¼öµ¿°üÂûÀÚ
  • passive sensitization
    ¼öµ¿¹Î°¨È­
  • passive shimming
    ¼öµ¿º¸Á¤
  • passive smoking
    °£Á¢Èí¿¬
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reversed rhythm
    ¿ªÀü¸®µë
  • passive congestion
    ¼öµ¿¿ïÇ÷
  • passive diffusion
    ¼öµ¿È®»ê
  • passive edema
    ¼öµ¿ºÎÁ¾
  • passive euthanasia
    ¼öµ¿¾È¶ô»ç
  • passive exercise
    Çǵ¿¿îµ¿
  • passive hemagglutination
    ¼öµ¿ÀûÇ÷±¸ÀÀÁý
  • passive hyperemia
    ¼öµ¿ÃæÇ÷
  • passive immunity
    ¼öµ¿¸é¿ª
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • passive movement
    Çǵ¿¿îµ¿
  • passive observer
    ¼öµ¿°üÂûÀÚ
  • passive
    ¼öµ¿-, Çǵ¿-
  • passive sensitization
    ¼öµ¿¹Î°¨
  • passive shimming
    ¼öµ¿º¸Á¤
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º.
  • anaphylaxis,arachidonic acid metabolitesin
    ¾Æ¶ó۵·»ê ´ë»ç¹°Áú(¡­ß« ÓÛÞóÚªòõ)
  • antiserum anaphylaxis
    Ç×Ç÷û¾Æ³ªÇʶô½Ã.
  • antiserum anaphylaxis
    Ç×Ç÷û¾Æ³ªÇʶô½Ã½º.
  • generalized anaphylaxis
    Àü½Å¾Æ³ªÇʶô ½Ã½º.
  • generalized anaphylaxis
    Àü½Å ¾Æ³ªÇʶô½Ã½º
  • heterologous anaphylaxis
    ÀÌÁ¾¾Æ³ªÇʶô½Ã.
  • histamine, anaphylaxis
    È÷½ºÅ¸¹Î, ¾Æ³ªÆÈ¶ô½Ã¼º
  • homologous anaphylaxis
    µ¿Á¾(ÔÒðú)¾Æ³ªÇʶô½Ã.
  • homologous anaphylaxis
    µ¿Á¾(ÔÒðú)¾Æ³ªÇʶô½Ã½º.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reversed coarctation
    ¿ªÃàÂø.
  • reversed coarctation
    ¿ªÃàÂø(¿ªÃàÂø)
  • reversed crossing
    ¿ª±³Â÷(æ½Îßó¬) ¡ì¸Á¸·ÀÇ¡í.
  • reversed crossing phenomenon
    ¿ª±³Â÷Çö»ó(æ½Îßó¬úÞßÚ) ¸Á¸·ÀÇ .
  • reversed current
    ¿ªÀü·ù(æ½ï³êü).
  • reversed occlusion
    ¹Ý´ë±³ÇÕ(ÚãÓßÎáùê).
  • reversed peristalsis
    ¿ª¿¬µ¿(æ½âÍÔÑ).
  • reversed polarization
    ¿ªÀüºÐ±Ø(æ½ï®ÝÂп).
  • reversed real image
    µµ¸³½Ç»ó(Óîí¡ãùßÒ).
  • reversed rhythm
    ¿ªÀü½É¹Ú(æ½ï®ãýÚÑ).
  • reversed rhythm
    ¿ªÀü½É¹Ú(æ½ï®ãýÚÑ)
  • anaphylaxis
    °ú¹ÎÁõ, ¾Æ³ªÇʶô½Ã½º
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º, °ú¹ÎÁõ(ΦÚÂñø)
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã½º.
  • anaphylaxis
    ¾Æ³ªÇʶô½Ã.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive transfer
    ¼öµ¿ À̵¿(áôÔÑì¹ÔÑ)
  • passive transport
    ¼öµ¿ ¼ö¼Û(áôÔÑâÃáê)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ASA acetylsalicylic acid; active systemic anaphylaxis; Adams-Stokes attack; American Society of Anesthes...
BK-A basophil kallikrein of anaphylaxis
ECFA, ECF-A eosinophilic chemotactic factor of anaphylaxis
PAF-A platelet-activating factor of anaphylaxis
SRF-A slow-reacting factor-anaphylaxis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IA Idiopathic Anaphylaxis
SRS-A Slow Reacting Substance of Anaphylaxis
ASA active systemic anaphylaxis
ECF-A eosinophil chemotactic factor of anaphylaxis
RCA reverse cutaneous anaphylaxis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • passive stretching
    ¼öµ¿Àû ½ÅÀå
  • passive transport
    Çǵ¿Àû ¿î¹Ý, Çǵ¿Àû À̵¿, ¼öµ¿Àû À̵¿
  • passive-aggressive personality
    ¼öµ¿Àû °ø°Ý¼º ÀΰÝ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
aggregate anaphylaxis <pharmacology> As opposed to prophylaxis. A system or treatment that leads to damaging effects on the organism.
<immunology> Now reserved for those inflammatory reactions resulting from combination of a soluble antigen with IgE bound to a mast cell that leads to degranulation of the mast cell and release of histamine and histamine like substances, causing localised or global immune reponses.
Results in an acute allergic reaction with shortness of breath, rash, wheezing, hypotension.
See: hypersensitivity.
(18 Nov 1997)
anaphylaxis <pharmacology> As opposed to prophylaxis. A system or treatment that leads to damaging effects on the organism.
<immunology> Now reserved for those inflammatory reactions resulting from combination of a soluble antigen with IgE bound to a mast cell that leads to degranulation of the mast cell and release of histamine and histamine like substances, causing localised or global immune reponses.
Results in an acute allergic reaction with shortness of breath, rash, wheezing, hypotension.
See: hypersensitivity.
(18 Nov 1997)
antiserum anaphylaxis A reaction resulting from inoculation of antigen in an animal previously inoculated intravenously with specific antiserum from another animal, a latent period being required between the two inoculations.
Synonym: antiserum anaphylaxis.
(05 Mar 2000)
generalised anaphylaxis The immediate response, involving smooth muscles and capillaries throughout the body of a sensitised individual, that follows intravenous (and occasionally intracutaneous) injection of antigen (allergen).
See: anaphylactic shock.
Synonym: systemic anaphylaxis.
(05 Mar 2000)
pharmacologic mediators of anaphylaxis Substances released from mast (and other) cells by the reaction of antigen and specific homocytotropic antibody on their surfaces; they include histamine, slow-reacting substance of anaphylaxis (SRS-A), bradykinin, and (in some species of animals) serotonin.
(05 Mar 2000)
chronic anaphylaxis A haemorrhagic and necrotizing inflammation developing in the ileum (and also the colon) of sensitised dogs when they are fed a second dose of the sensitizing material.
Synonym: chronic anaphylaxis.
(05 Mar 2000)
slow-reacting factor of anaphylaxis Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules.
Compare: peptidyl leukotrienes.
Synonym: slow-reacting factor of anaphylaxis.
(05 Mar 2000)
slow reacting substance of anaphylaxis <immunology> Potent bronchoconstrictor and inflammatory agent released by mast cells, an important mediator of allergic bronchial asthma.
A mixture of three leukotrienes (LTC4 mainly, LTD4 and LTE4)
(18 Nov 1997)
systemic anaphylaxis The immediate response, involving smooth muscles and capillaries throughout the body of a sensitised individual, that follows intravenous (and occasionally intracutaneous) injection of antigen (allergen).
See: anaphylactic shock.
Synonym: systemic anaphylaxis.
(05 Mar 2000)
inverse anaphylaxis Anaphylactic shock in an animal (e.g., guinea pig) whose tissues contain Forssman antigen, resulting from an intravenous injection of serum that contains Forssman's antibody.
(05 Mar 2000)
eosinophil chemotactic factor of anaphylaxis A peptide (MW 500 to 600) that is chemotactic for eosinophilic leukocytes and is released from disrupted mast cells.
(05 Mar 2000)
local anaphylaxis The immediate, transient kind of response that follows the injection of antigen (allergen) into the skin of a sensitised individual and is limited to the area surrounding the site of inoculation.
See: skin test.
(05 Mar 2000)
artificial passive immunity See: acquired immunity.
(05 Mar 2000)
passive Neither spontaneous nor active, not produced by active efforts.
Origin: L. Passivus
(18 Nov 1997)
passive agglutination Agglutination of particles that have been coated with soluble antigen, by antiserum specific for the adsorbed antigen.
Synonym: indirect agglutination.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive voice
    ¼öµ¿ÅÂ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á